GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of reading SURMOUNT threads from 2024 and half of it aged badly — 54 comments in the full submission. View in context.
3.7k
c/trialwatch·submitted 1 year ago by u/yannick_salinas

reading SURMOUNT threads from 2024 and half of it aged badly

Trial Databranch of 8 comments

reading SURMOUNT threads from 2024 and half of it aged badly. Making the case below, and I expect to lose some of it in the comments. Quoted a figure here confidently, got asked whether it was ITT, went and checked, and it was not. Learned something. Spent an evening with the appendix tables and found the subgroup…

Read the full submission and all 54 comments →

This branch

8 comments, started 1 year ago
u/ewan_tulloch76 points·1 year ago

Compared myself to a trial mean for about six months before realising the trial arm had dietitian contact every fortnight.

replysharereportpermalink
u/trialwatch_theoMOD50 points·1 year ago

Added the trial identifier to the title so this thread is findable in two years.

replysharereportpermalink
u/hazard_ratio_halstats35 points·1 year ago

Small fix — that was the cardiovascular outcomes trial, so weight was a secondary endpoint and the population was different.

replysharereportpermalink
u/zaid_roos13 points·1 year ago

a mean is not a promise

replysharereportpermalink
u/marit_laurent8 points·1 year ago·edited

a mean is not a promise

Disagreeing with this line: that is a relative reduction and the absolute numbers are considerably less dramatic.

replysharereportpermalink
u/prior_auth_painappeals4 points·1 year ago

This. Intention-to-treat versus completer analysis routinely moves the headline by several points.

replysharereportpermalink
u/hugo_norgaard3 points·1 year ago

Argued for a week about a result and then read the limitations section, which conceded most of my opponent’s point.

replysharereportpermalink
u/eu_apotheke_a47 points·1 year ago

How long was the randomised phase before any extension?

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.